Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64
Published . Updated .
The average one-year price target for Lexicon Pharmaceuticals (NASDAQCM:LXRX) has been revised to $4.64 / share. This is an increase of 17.91% from the prior estimate of $3.93 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do n
Directly affected
- LXRX Lexicon Pharmaceuticals
Named in this report.
Indirectly affected
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDE ISHARES LIFEPATH TARGET DATE 2045 ETF USD
GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Lexicon Pharmaceuticals (NASDAQCM:LXRX) has been revised to $4.64 / share. This is an increase of 17.91% from the prior estimate of $3.93 dated September 11, 2026. These figures represent aggregate ana…
Source: Nasdaq Markets
Lexicon Pharmaceuticals (LXRX) since this story, compared with the market
Since the first closing price after “Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64,” Lexicon Pharmaceuticals (LXRX) is -12.00%. The S&P 500 fund (SPY) is -1.08% over the same days, a -10.92% difference versus the market.
Who gains and who loses around Lexicon Pharmaceuticals (LXRX)
Companies mentioned with this story
- LXRX Lexicon Pharmaceuticals
In “Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64,” Lexicon Pharmaceuticals (LXRX) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names LEXICON PHARMACEUTICALS INC in the headline; GA resolved that company to LXRX
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
For “Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64,” T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64.” Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FGSI Ft Vest Growth Strength & Target Income Etf
In “Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64,” Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence. Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64.” Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
In “Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64,” Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDE Ishares Lifepath Target Date 2045 Etf Usd
For “Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64,” Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Lexicon Pharmaceuticals (LXRX)
“Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64” (2 Oct 2026) reaches Lexicon Pharmaceuticals (LXRX) through this story.
What ties Lexicon Pharmaceuticals (LXRX) to the headline is this: The reported development directly names LEXICON PHARMACEUTICALS INC in the headline; GA resolved that company to LXRX
A second company, T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ), is listed for a different reason: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Lexicon Pharmaceuticals (LXRX) price range
BTCZ traded between 2.69 and 3.21 across 20 sessions. The latest close on file is 3.06. DOGG traded between 20.68 and 22.21 across 20 sessions. The latest close on file is 21.99. LXRX traded between 1.51 and 2.06 across 16 sessions. The latest close on file is 1.54.
A simple score for Lexicon Pharmaceuticals (LXRX)
46 out of 100
“Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.